Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
10.04. | EXACT Therapeutics AS: Additional promising clinical data from EXACT Therapeutics' ongoing ACTIVATE study presented at AACR Annual Meeting | 1 | Oslo Børs | ||
22.01. | EXACT Therapeutics AS: Financial calendar | 1 | Oslo Børs | ||
20.12.23 | EXACT Therapeutics AS - Share capital increase registered. Correction. | 1 | Oslo Børs | ||
20.12.23 | EXACT Therapeutics AS - Share capital increase registered | - | Oslo Børs | ||
14.12.23 | EXACT Therapeutics AS: EXACT Therapeutics presenting at DNB Nordic Healthcare conference December 14 | 1 | Oslo Børs | ||
01.12.23 | EXACT Therapeutics AS: Primary insider notices | 1 | Oslo Børs | ||
30.11.23 | EXACT Therapeutics AS: Contemplated Private Placement | - | Oslo Børs | ||
31.10.23 | EXACT Therapeutics AS: EXACT Therapeutics receives regulatory approval to start recruitment of patients at Oslo University hospital | - | Oslo Børs |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 13,990 | +2,12 % | Evotec, HelloFresh, Lanxess, Nordex, ThyssenKrupp, Varta und Co. - Aktien-Positionen der Shortseller | Wer Aktien leer verkauft, das sogenannte Shortselling, muss Transparenzpflichten erfüllen. Wir werfen einen Blick auf aktuelle Shortseller-Meldungen. Geregelt sind diese in der EU-Leerverkaufsverordnung... ► Artikel lesen | |
QIAGEN | 38,505 | +0,18 % | Qiagen: Aufschwung in der zweiten Jahreshälfte | Analysten der Deutschen Bank erwarten beim Jahresauftakt von Qiagen keine Überraschungen. Das Unternehmen prognostiziert einen Umsatz von rund 455 Millionen Dollar, das wäre ein Minus von rund 6 Prozent.... ► Artikel lesen | |
MORPHOSYS | 67,80 | +0,07 % | EQS-PVR: MorphoSys AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: MorphoSys AG
MorphoSys AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
16.04.2024 / 16:00 CET/CEST
Veröffentlichung... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 40,520 | +1,05 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024 | ||
RECURSION PHARMACEUTICALS | 7,370 | +0,27 % | Recursion Pharmaceuticals, Inc.: Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer | Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion's Board of DirectorsSALT LAKE... ► Artikel lesen | |
DAY ONE BIOPHARMACEUTICALS | 15,030 | +0,47 % | Day One Biopharmaceuticals, Inc.: Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress | PDUFA target action date for tovorafenib NDA in relapsed or progressive pLGG remains set for April 30, 2024 Phase 2 FIREFLY-1 tovorafenib registrational data published in Nature Medicine Ended 2023... ► Artikel lesen | |
IMMUNOVANT | 28,370 | +0,53 % | Here's Why You Should Add Immunovant (IMVT) to Your Portfolio | ||
JANUX THERAPEUTICS | 46,130 | -5,26 % | Janux a new buy at Jones on lead assets for solid tumors | ||
AVIDITY BIOSCIENCES | 23,090 | +1,58 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, March 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide... ► Artikel lesen | |
PRAXIS PRECISION MEDICINES | 46,110 | -1,66 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
BEAM THERAPEUTICS | 23,590 | -1,30 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
KYMERA THERAPEUTICS | 34,750 | +2,30 % | Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) | ||
ARCUTIS BIOTHERAPEUTICS | 8,980 | -1,32 % | Arcutis Biotherapeutics, Inc.: Arcutis Appoints David Topper as Chief Financial Officer | WESTLAKE VILLAGE, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage company focused on developing meaningful innovations in immuno-dermatology... ► Artikel lesen | |
HUMACYTE | 3,680 | -0,54 % | Here's why the Humacyte (HUMA) stock price is pumping | ||
ARVINAS | 34,970 | +0,72 % | Arvinas Enters Deal With Novartis For License Of ARV-766, Sale Of AR-V7 Program; Stock Jumps | BASEL (dpa-AFX) - Arvinas, Inc. (ARVN) has entered into an exclusive strategic license agreement with Novartis (NVS) for the worldwide development and commercialization of ARV-766, the company's... ► Artikel lesen |